EP Patent

EP3353182A1 — Tetrahydropyrano[3,4-d][1,3]oxazin derivatives and their use as bace inhibitors

Assigned to Pfizer Inc · Expires 2018-08-01 · 8y expired

What this patent protects

The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula (I), wherein the variables R 1 , R 2 , R 3 , R 4 and X are as defined in the specification. C…

USPTO Abstract

The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula (I), wherein the variables R 1 , R 2 , R 3 , R 4 and X are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Drugs covered by this patent

Patent Metadata

Patent number
EP3353182A1
Jurisdiction
EP
Classification
—
Expires
2018-08-01
Drug substance claim
No
Drug product claim
No
Assignee
Pfizer Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.